Pharmaron (Stock Code: 300759.SZ/3759.HK) is a leading fully integrated pharmaceutical service provider platform supporting the life science industry. Established in 2004, our firm commitment to excellence is exemplified by the continuous investment in our highly skilled team and 20 state-of-the-art facilities, ensuring excellent quality throughout our operations. As an integrated service provider, Pharmaron seamlessly supports clients from Discovery to Market, offering a comprehensive suite of services for the entire drug discovery, preclinical, clinical development, and manufacturing continuum. Our commitment extends across diverse therapeutic modalities, encompassing small molecules, biologics, medical devices and cell and gene therapy products. Boasting a global presence with over 21,000 skilled professionals and operational hubs in China, the U.S., and the U.K., we have consistently delivered innovative solutions. Our partner’s success is our mission. Supporting the development and successful approval of medicines for the patients

Key highlights of Pharmaron’s diverse service capabilities:
• Synthetic, medicinal and analytical chemistry
• in vitro and in vivo Biology
• ADME/DMPK
• In vivo Pharmacology
• Drug safety assessment
• Recombinant protein expression, purification and characterization
• Custom antibody expression
• Biophysical screening
• Radiochemistry and isotopically labelled metabolism
• Chemical & pharmaceutical development
• Process Chemistry & GMP API synthesis
• GMP Formulation preparation
• Clinical Pharmacology
• GMP API Manufacturing
• Clinical Trials
• GMP Drug product manufacturing
• Clinical development, including applications of 14C microtracer AMS technology
• Plasmid and AAV Manufacturing
• Analytical Services
• Cell and Gene Therapy preclinical services (IND package)
• Biologics and Biosimilars Manufacturing
• ADC
• Ophthalmology preclinical development services (small molecule, CGT and medical device)
• Clinical Trials